US industry critical of FDA tracking programme
This article was originally published in Clinica
Executive Summary
Medical devices should be subject to tracking by the FDA only if it can be shown that "they are reasonably likely to experience a failure" as well as showing that "such a failure would be reasonably likely to have serious adverse health consequences," according to the Health Industry Manufacturers Association (HIMA) in the US.